BioVie shares surge 12.80% premarket as investor webinar highlights drug candidates and multi-billion-dollar market potential.

BioVie Inc. (NASDAQ: BIVI) surged 12.8% in premarket trading following the announcement of an exclusive investor webinar on March 4, 2026, hosted by RedChip Companies. The event will feature CEO Cuong Do discussing the company’s lead drug candidate, bezisterim (NE3107), targeting Alzheimer’s, Parkinson’s, and Long COVID, as well as BIV201, an orphan drug candidate for cirrhosis and ascites. The webinar highlights potential late-stage clinical advancements, strong safety data, and multi-billion-dollar market opportunities, positioning BioVie for value creation through pivotal milestones and partnerships. The premarket rally reflects investor optimism over the detailed clinical updates and strategic progress outlined in the event.